Isomorphic Labs raises $5 billion to advance AI drug candidates
Original title: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
The Series C, co-led by Greenoaks and Sequoia, follows a $2.1 billion round in May; valuation was not disclosed.
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, raised $5 billion in a Series C to move candidates toward clinical trials. Greenoaks and Sequoia Capital co-led, with Andreessen Horowitz joining existing backers including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The company cites positive preclinical results in oncology and immunology and existing deals with Eli Lilly, Novartis, and Johnson & Johnson. Funds will expand its simulation-based drug-design engine, which builds on AlphaFold.
Unconfirmed: A $50 billion valuation is only what Bloomberg reported the lab was seeking; Isomorphic did not confirm it.
- Founder Demis Hassabis left as DeepMind head and became DeepMind chairman.
- Hassabis and John Jumper won the chemistry Nobel for AlphaFold.
- Bloomberg earlier reported a target valuation of $50 billion.
- The company did not disclose the new valuation.
From the original article
1 min read at techcrunch.com
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.
By Ram Iyer · techcrunch.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.